Utang jangka cendhak marang modal PolyPid (PYPD)

PolyPid Ltd. (PYPD) develops PLEX polymer films for targeted drug delivery, offering D-PLEX100 to protect wounds from infection for one month. Business funding relies on capital for conducting clinical tests of new antibiotic delivery systems. This price chart reflects the 0.26 metric, while the biotech firm completes the final stage of gel trials and seeks US partners for commercialization.

To identify fundamentally resilient assets, investors must evaluate the balance between expansion and financial security. This indicator measures the share of long-term liabilities (over one year) within the capital structure, allowing for the tracking of liquidity risks during the scaling of PLEX technology for infection control by monitoring the ratio of short-term debt (under one year) to equity, thereby determining the funding reliability of PolyPid Ltd. (PYPD) and its leadership within its segment.